Search
Paquinimod
go.drugbank.com/drugs/DB13118InvestigationalThe disease affects mainly women of fertile age and progresses in flares with relatively symptom free periods in between. … Paquinimod is developed for the treatment of SLE (Systemic Lupus Erythematosus), which is an autoimmune disease.
Abdavomeran
go.drugbank.com/drugs/DB15695Investigational[L15012] BNT162b1 is undergoing further evaluation in clinical trials in both the USA (NCT04368728) and Germany (NCT04380701). … [L15012] The modRNA is formulated in lipid nanoparticles for delivery via intramuscular injection.
Bacteriochlorophyll A
go.drugbank.com/drugs/DB01853ExperimentalA specific bacteriochlorophyll that is similar in structure to CHLOROPHYLL A.
Cavosonstat
go.drugbank.com/drugs/DB14775InvestigationalCavosonstat is under investigation in clinical trial NCT02589236 (Study of Cavosonstat (N91115) in Patients With CF Homozygous for the F508del-CFTR Mutation).
Bermekimab
go.drugbank.com/drugs/DB14947InvestigationalBermekimab is under investigation in clinical trial NCT01384630 (Safety, Pharmacokinetics, and Efficacy of RA-18C3 in Subjects With Moderate to Severe Psoriasis).
Edasalonexent
go.drugbank.com/drugs/DB15010InvestigationalEdasalonexent is under investigation in clinical trial NCT01511900 (A Multiple Ascending Dose Study of CAT-1004 in Patients With Type 2 Diabetes).
CXA-10
go.drugbank.com/drugs/DB15026InvestigationalCXA-10 is under investigation in clinical trial NCT03422510 (FIRSTx - A Study of Oral CXA-10 in Primary Focal Segmental Glomerulosclerosis (FSGS)).
Vunakizumab
go.drugbank.com/drugs/DB15154InvestigationalVunakizumab is under investigation in clinical trial NCT03463187 (Multi-Dose Study of SHR-1314 in Subjects With Moderate-to-severe Plaque Psoriasis).
Ofranergene obadenovec
go.drugbank.com/drugs/DB15175InvestigationalOfranergene obadenovec is under investigation in clinical trial NCT01229865 (Safety and Efficacy of VB-111 in Subjects With Advanced Differentiated Thyroid Cancer).
MK-0533
go.drugbank.com/drugs/DB15242InvestigationalMK-0533 is under investigation in clinical trial NCT00543959 (Efficacy and Tolerability of MK0533 in Patients With Type 2 Diabetes (0533-005)).